Personalized Medicine's Coming of Age: One Drug, One Patient

Clin Cancer Res. 2023 Sep 21. doi: 10.1158/1078-0432.CCR-23-2194. Online ahead of print.ABSTRACTA dendritic cell/myeloma fusion vaccine, given with lenalidomide and GM-CSF, did not result in a statistically significant increase in CR rates at 1-year post-transplant but was associated with a significant increase in circulating multiple myeloma-reactive lymphocytes indicative of tumor-specific immunity.PMID:37733765 | DOI:10.1158/1078-0432.CCR-23-2194

Source: Cell Research - September 21, 2023 Category: Cytology Authors: Muzaffar H Qazilbash Larry W Kwak Source Type: research